PandemieGrippaleV1, PascalFrancis, Corpus, bibRecord, 000021

Safety of inactivated monovalent pandemic (H1N1) 2009 vaccination during pregnancy: A population-based study in Taiwan

Identifieur interne : 000021 ( PascalFrancis/Corpus ); précédent : 000020; suivant : 000022

Safety of inactivated monovalent pandemic (H1N1) 2009 vaccination during pregnancy: A population-based study in Taiwan

Auteurs : Wan-Ting Huang ; Fa-Wei Tang ; Shu-Er Yang ; Yi-Chien Chih ; Jen-Hsiang Chuang

Source :

Vaccine [ 0264-410X ] ; 2014.

RBID : Pascal:14-0276947

Descripteurs français

Pascal (Inist)
- Virus grippal A, Vaccination, Gestation, Taiwan, Adjuvant immunologique, Vaccin, Virus grippal A(H1N1).

English descriptors

KwdEn :
- Immunological adjuvant, Influenza A virus, Influenzavirus A(H1N1), Pregnancy, Taiwan, Vaccination, Vaccine.

Abstract

Background: Pregnant women were prioritized for H1N1 vaccination during the 2009-2010 pandemic. Safety concerns exist with vaccinating pregnant women, particularly in their first trimesters. Methods: We linked computerized data on H1N1 vaccination, National Health Insurance, and Taiwan Birth Registry and identified events of spontaneous abortions (SABs) and all singleton births that occurred/delivered during November 1, 2009-September 30, 2010. The observation period for each case of SAB (6-19 weeks gestation) was divided into period at risk (1-28 days after vaccination) and control periods (the remaining person-days until SAB). The self-controlled case series method for truncated observational periods assessed the incidence rate ratio (IRR) of SAB during the 1-28 days compared with those in the control period. The case-control design matched each case of adverse fetal outcomes to up to 10 controls on fetal sex and year/month of pregnancy onset, and calculated matched odds ratio (OR) on H1N1 vaccination at <14 or ≥ 14 weeks gestation. Results: Sixty-five women with SAB had received H1N1 vaccination at 6-19 weeks gestation. The IRR of SAB for the risk period 1-28 days was 1.03 (95% confidence interval [CI] 0.55-1.93). Among the 147,294 live births and 1354 stillbirths, maternal H1N1 vaccine receipt at <14 weeks gestation was associated with significantly reduced likelihood of small for gestational age (SGA) birth (OR 0.72, 95% CI 0.61-0.84) and birth defect (OR 0.46,95% CI 0.22-1.00), whereas receipt at ≥14 weeks gestation was associated with significantly reduced likelihood of stillbirth (OR 0.63, 95% CI 0.46-0.86), prematurity (OR 0.90, 95% CI 0.83-0.97), low birth weight (OR 0.81, 95% CI 0.74-0.88), and SGA birth (OR 0.90, 95% CI 0.84-0.97). Conclusions: H1N1 vaccination during pregnancy did not increase risk of SAB or adverse fetal outcomes.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0264-410X`
A02	`01`			`@0 VACCDE`
A03		`1`		`@0 Vaccine`
A05				`@2 32`
A06				`@2 48`
A08	`01`	`1`	`ENG`	`@1 Safety of inactivated monovalent pandemic (H1N1) 2009 vaccination during pregnancy: A population-based study in Taiwan`
A11	`01`	`1`		`@1 HUANG (Wan-Ting)`
A11	`02`	`1`		`@1 TANG (Fa-Wei)`
A11	`03`	`1`		`@1 YANG (Shu-Er)`
A11	`04`	`1`		`@1 CHIH (Yi-Chien)`
A11	`05`	`1`		`@1 CHUANG (Jen-Hsiang)`
A14	`01`			`@1 Taiwan Centers for Disease Control, 6 Linsen S. Road @2 Taipei 10050 @3 TWN @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut.`
A14	`02`			`@1 Institute of Biomedical Informatics & Institute of Public Health, National Yang-Ming University, 155 Section 2, Linong Street @2 Taipei 11221 @3 TWN @Z 5 aut.`
A20				`@1 6463-6468`
A21				`@1 2014`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20289 @5 354000502696130230`
A44				`@0 0000 @1 © 2014 INIST-CNRS. All rights reserved.`
A45				`@0 35 ref.`
A47	`01`	`1`		`@0 14-0276947`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Vaccine`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Background: Pregnant women were prioritized for H1N1 vaccination during the 2009-2010 pandemic. Safety concerns exist with vaccinating pregnant women, particularly in their first trimesters. Methods: We linked computerized data on H1N1 vaccination, National Health Insurance, and Taiwan Birth Registry and identified events of spontaneous abortions (SABs) and all singleton births that occurred/delivered during November 1, 2009-September 30, 2010. The observation period for each case of SAB (6-19 weeks gestation) was divided into period at risk (1-28 days after vaccination) and control periods (the remaining person-days until SAB). The self-controlled case series method for truncated observational periods assessed the incidence rate ratio (IRR) of SAB during the 1-28 days compared with those in the control period. The case-control design matched each case of adverse fetal outcomes to up to 10 controls on fetal sex and year/month of pregnancy onset, and calculated matched odds ratio (OR) on H1N1 vaccination at <14 or ≥ 14 weeks gestation. Results: Sixty-five women with SAB had received H1N1 vaccination at 6-19 weeks gestation. The IRR of SAB for the risk period 1-28 days was 1.03 (95% confidence interval [CI] 0.55-1.93). Among the 147,294 live births and 1354 stillbirths, maternal H1N1 vaccine receipt at <14 weeks gestation was associated with significantly reduced likelihood of small for gestational age (SGA) birth (OR 0.72, 95% CI 0.61-0.84) and birth defect (OR 0.46,95% CI 0.22-1.00), whereas receipt at ≥14 weeks gestation was associated with significantly reduced likelihood of stillbirth (OR 0.63, 95% CI 0.46-0.86), prematurity (OR 0.90, 95% CI 0.83-0.97), low birth weight (OR 0.81, 95% CI 0.74-0.88), and SGA birth (OR 0.90, 95% CI 0.84-0.97). Conclusions: H1N1 vaccination during pregnancy did not increase risk of SAB or adverse fetal outcomes.
C02	`01`	`X`		`@0 002A05F04`
C02	`02`	`X`		`@0 002A05C10`
C03	`01`	`X`	`FRE`	`@0 Virus grippal A @2 NW @5 01`
C03	`01`	`X`	`ENG`	`@0 Influenza A virus @2 NW @5 01`
C03	`01`	`X`	`SPA`	`@0 Influenza A virus @2 NW @5 01`
C03	`02`	`X`	`FRE`	`@0 Vaccination @5 05`
C03	`02`	`X`	`ENG`	`@0 Vaccination @5 05`
C03	`02`	`X`	`SPA`	`@0 Vacunación @5 05`
C03	`03`	`X`	`FRE`	`@0 Gestation @5 06`
C03	`03`	`X`	`ENG`	`@0 Pregnancy @5 06`
C03	`03`	`X`	`SPA`	`@0 Gestación @5 06`
C03	`04`	`X`	`FRE`	`@0 Taiwan @2 NG @5 07`
C03	`04`	`X`	`ENG`	`@0 Taiwan @2 NG @5 07`
C03	`04`	`X`	`SPA`	`@0 Taiwan @2 NG @5 07`
C03	`05`	`X`	`FRE`	`@0 Adjuvant immunologique @5 08`
C03	`05`	`X`	`ENG`	`@0 Immunological adjuvant @5 08`
C03	`05`	`X`	`SPA`	`@0 Coadyuvante inmunológico @5 08`
C03	`06`	`X`	`FRE`	`@0 Vaccin @5 09`
C03	`06`	`X`	`ENG`	`@0 Vaccine @5 09`
C03	`06`	`X`	`SPA`	`@0 Vacuna @5 09`
C03	`07`	`X`	`FRE`	`@0 Virus grippal A(H1N1) @4 CD @5 96`
C03	`07`	`X`	`ENG`	`@0 Influenzavirus A(H1N1) @4 CD @5 96`
C07	`01`	`X`	`FRE`	`@0 Influenzavirus A @2 NW`
C07	`01`	`X`	`ENG`	`@0 Influenzavirus A @2 NW`
C07	`01`	`X`	`SPA`	`@0 Influenzavirus A @2 NW`
C07	`02`	`X`	`FRE`	`@0 Orthomyxoviridae @2 NW`
C07	`02`	`X`	`ENG`	`@0 Orthomyxoviridae @2 NW`
C07	`02`	`X`	`SPA`	`@0 Orthomyxoviridae @2 NW`
C07	`03`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`03`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`03`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`04`	`X`	`FRE`	`@0 Asie @2 NG`
C07	`04`	`X`	`ENG`	`@0 Asia @2 NG`
C07	`04`	`X`	`SPA`	`@0 Asia @2 NG`
C07	`05`	`X`	`FRE`	`@0 Extrême Orient @2 NG @5 13`
C07	`05`	`X`	`ENG`	`@0 Far east @2 NG @5 13`
C07	`05`	`X`	`SPA`	`@0 Extremo Oriente @2 NG @5 13`
C07	`06`	`X`	`FRE`	`@0 Zone subtropicale @5 16`
C07	`06`	`X`	`ENG`	`@0 Subtropical zone @5 16`
C07	`06`	`X`	`SPA`	`@0 Zona subtropical @5 16`
N21				`@1 349`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 14-0276947 INIST
ET :	Safety of inactivated monovalent pandemic (H1N1) 2009 vaccination during pregnancy: A population-based study in Taiwan
AU :	HUANG (Wan-Ting); TANG (Fa-Wei); YANG (Shu-Er); CHIH (Yi-Chien); CHUANG (Jen-Hsiang)
AF :	Taiwan Centers for Disease Control, 6 Linsen S. Road/Taipei 10050/Taïwan (1 aut., 2 aut., 3 aut., 4 aut., 5 aut.); Institute of Biomedical Informatics & Institute of Public Health, National Yang-Ming University, 155 Section 2, Linong Street/Taipei 11221/Taïwan (5 aut.)
DT :	Publication en série; Niveau analytique
SO :	Vaccine; ISSN 0264-410X; Coden VACCDE; Royaume-Uni; Da. 2014; Vol. 32; No. 48; Pp. 6463-6468; Bibl. 35 ref.
LA :	Anglais
EA :	Background: Pregnant women were prioritized for H1N1 vaccination during the 2009-2010 pandemic. Safety concerns exist with vaccinating pregnant women, particularly in their first trimesters. Methods: We linked computerized data on H1N1 vaccination, National Health Insurance, and Taiwan Birth Registry and identified events of spontaneous abortions (SABs) and all singleton births that occurred/delivered during November 1, 2009-September 30, 2010. The observation period for each case of SAB (6-19 weeks gestation) was divided into period at risk (1-28 days after vaccination) and control periods (the remaining person-days until SAB). The self-controlled case series method for truncated observational periods assessed the incidence rate ratio (IRR) of SAB during the 1-28 days compared with those in the control period. The case-control design matched each case of adverse fetal outcomes to up to 10 controls on fetal sex and year/month of pregnancy onset, and calculated matched odds ratio (OR) on H1N1 vaccination at <14 or ≥ 14 weeks gestation. Results: Sixty-five women with SAB had received H1N1 vaccination at 6-19 weeks gestation. The IRR of SAB for the risk period 1-28 days was 1.03 (95% confidence interval [CI] 0.55-1.93). Among the 147,294 live births and 1354 stillbirths, maternal H1N1 vaccine receipt at <14 weeks gestation was associated with significantly reduced likelihood of small for gestational age (SGA) birth (OR 0.72, 95% CI 0.61-0.84) and birth defect (OR 0.46,95% CI 0.22-1.00), whereas receipt at ≥14 weeks gestation was associated with significantly reduced likelihood of stillbirth (OR 0.63, 95% CI 0.46-0.86), prematurity (OR 0.90, 95% CI 0.83-0.97), low birth weight (OR 0.81, 95% CI 0.74-0.88), and SGA birth (OR 0.90, 95% CI 0.84-0.97). Conclusions: H1N1 vaccination during pregnancy did not increase risk of SAB or adverse fetal outcomes.
CC :	002A05F04; 002A05C10
FD :	Virus grippal A; Vaccination; Gestation; Taiwan; Adjuvant immunologique; Vaccin; Virus grippal A(H1N1)
FG :	Influenzavirus A; Orthomyxoviridae; Virus; Asie; Extrême Orient; Zone subtropicale
ED :	Influenza A virus; Vaccination; Pregnancy; Taiwan; Immunological adjuvant; Vaccine; Influenzavirus A(H1N1)
EG :	Influenzavirus A; Orthomyxoviridae; Virus; Asia; Far east; Subtropical zone
SD :	Influenza A virus; Vacunación; Gestación; Taiwan; Coadyuvante inmunológico; Vacuna
LO :	INIST-20289.354000502696130230
ID :	14-0276947

Links to Exploration step

Pascal:14-0276947

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Safety of inactivated monovalent pandemic (H1N1) 2009 vaccination during pregnancy: A population-based study in Taiwan</title>
<author><name sortKey="Huang, Wan Ting" sort="Huang, Wan Ting" uniqKey="Huang W" first="Wan-Ting" last="Huang">Wan-Ting Huang</name>
<affiliation><inist:fA14 i1="01"><s1>Taiwan Centers for Disease Control, 6 Linsen S. Road</s1>
<s2>Taipei 10050</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tang, Fa Wei" sort="Tang, Fa Wei" uniqKey="Tang F" first="Fa-Wei" last="Tang">Fa-Wei Tang</name>
<affiliation><inist:fA14 i1="01"><s1>Taiwan Centers for Disease Control, 6 Linsen S. Road</s1>
<s2>Taipei 10050</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yang, Shu Er" sort="Yang, Shu Er" uniqKey="Yang S" first="Shu-Er" last="Yang">Shu-Er Yang</name>
<affiliation><inist:fA14 i1="01"><s1>Taiwan Centers for Disease Control, 6 Linsen S. Road</s1>
<s2>Taipei 10050</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chih, Yi Chien" sort="Chih, Yi Chien" uniqKey="Chih Y" first="Yi-Chien" last="Chih">Yi-Chien Chih</name>
<affiliation><inist:fA14 i1="01"><s1>Taiwan Centers for Disease Control, 6 Linsen S. Road</s1>
<s2>Taipei 10050</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chuang, Jen Hsiang" sort="Chuang, Jen Hsiang" uniqKey="Chuang J" first="Jen-Hsiang" last="Chuang">Jen-Hsiang Chuang</name>
<affiliation><inist:fA14 i1="01"><s1>Taiwan Centers for Disease Control, 6 Linsen S. Road</s1>
<s2>Taipei 10050</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Institute of Biomedical Informatics & Institute of Public Health, National Yang-Ming University, 155 Section 2, Linong Street</s1>
<s2>Taipei 11221</s2>
<s3>TWN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0276947</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0276947 INIST</idno>
<idno type="RBID">Pascal:14-0276947</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000021</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Safety of inactivated monovalent pandemic (H1N1) 2009 vaccination during pregnancy: A population-based study in Taiwan</title>
<author><name sortKey="Huang, Wan Ting" sort="Huang, Wan Ting" uniqKey="Huang W" first="Wan-Ting" last="Huang">Wan-Ting Huang</name>
<affiliation><inist:fA14 i1="01"><s1>Taiwan Centers for Disease Control, 6 Linsen S. Road</s1>
<s2>Taipei 10050</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tang, Fa Wei" sort="Tang, Fa Wei" uniqKey="Tang F" first="Fa-Wei" last="Tang">Fa-Wei Tang</name>
<affiliation><inist:fA14 i1="01"><s1>Taiwan Centers for Disease Control, 6 Linsen S. Road</s1>
<s2>Taipei 10050</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yang, Shu Er" sort="Yang, Shu Er" uniqKey="Yang S" first="Shu-Er" last="Yang">Shu-Er Yang</name>
<affiliation><inist:fA14 i1="01"><s1>Taiwan Centers for Disease Control, 6 Linsen S. Road</s1>
<s2>Taipei 10050</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chih, Yi Chien" sort="Chih, Yi Chien" uniqKey="Chih Y" first="Yi-Chien" last="Chih">Yi-Chien Chih</name>
<affiliation><inist:fA14 i1="01"><s1>Taiwan Centers for Disease Control, 6 Linsen S. Road</s1>
<s2>Taipei 10050</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chuang, Jen Hsiang" sort="Chuang, Jen Hsiang" uniqKey="Chuang J" first="Jen-Hsiang" last="Chuang">Jen-Hsiang Chuang</name>
<affiliation><inist:fA14 i1="01"><s1>Taiwan Centers for Disease Control, 6 Linsen S. Road</s1>
<s2>Taipei 10050</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Institute of Biomedical Informatics & Institute of Public Health, National Yang-Ming University, 155 Section 2, Linong Street</s1>
<s2>Taipei 11221</s2>
<s3>TWN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Immunological adjuvant</term>
<term>Influenza A virus</term>
<term>Influenzavirus A(H1N1)</term>
<term>Pregnancy</term>
<term>Taiwan</term>
<term>Vaccination</term>
<term>Vaccine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Virus grippal A</term>
<term>Vaccination</term>
<term>Gestation</term>
<term>Taiwan</term>
<term>Adjuvant immunologique</term>
<term>Vaccin</term>
<term>Virus grippal A(H1N1)</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: Pregnant women were prioritized for H1N1 vaccination during the 2009-2010 pandemic. Safety concerns exist with vaccinating pregnant women, particularly in their first trimesters. Methods: We linked computerized data on H1N1 vaccination, National Health Insurance, and Taiwan Birth Registry and identified events of spontaneous abortions (SABs) and all singleton births that occurred/delivered during November 1, 2009-September 30, 2010. The observation period for each case of SAB (6-19 weeks gestation) was divided into period at risk (1-28 days after vaccination) and control periods (the remaining person-days until SAB). The self-controlled case series method for truncated observational periods assessed the incidence rate ratio (IRR) of SAB during the 1-28 days compared with those in the control period. The case-control design matched each case of adverse fetal outcomes to up to 10 controls on fetal sex and year/month of pregnancy onset, and calculated matched odds ratio (OR) on H1N1 vaccination at <14 or ≥ 14 weeks gestation. Results: Sixty-five women with SAB had received H1N1 vaccination at 6-19 weeks gestation. The IRR of SAB for the risk period 1-28 days was 1.03 (95% confidence interval [CI] 0.55-1.93). Among the 147,294 live births and 1354 stillbirths, maternal H1N1 vaccine receipt at <14 weeks gestation was associated with significantly reduced likelihood of small for gestational age (SGA) birth (OR 0.72, 95% CI 0.61-0.84) and birth defect (OR 0.46,95% CI 0.22-1.00), whereas receipt at ≥14 weeks gestation was associated with significantly reduced likelihood of stillbirth (OR 0.63, 95% CI 0.46-0.86), prematurity (OR 0.90, 95% CI 0.83-0.97), low birth weight (OR 0.81, 95% CI 0.74-0.88), and SGA birth (OR 0.90, 95% CI 0.84-0.97). Conclusions: H1N1 vaccination during pregnancy did not increase risk of SAB or adverse fetal outcomes.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0264-410X</s0>
</fA01>
<fA02 i1="01"><s0>VACCDE</s0>
</fA02>
<fA03 i2="1"><s0>Vaccine</s0>
</fA03>
<fA05><s2>32</s2>
</fA05>
<fA06><s2>48</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Safety of inactivated monovalent pandemic (H1N1) 2009 vaccination during pregnancy: A population-based study in Taiwan</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>HUANG (Wan-Ting)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>TANG (Fa-Wei)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>YANG (Shu-Er)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>CHIH (Yi-Chien)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>CHUANG (Jen-Hsiang)</s1>
</fA11>
<fA14 i1="01"><s1>Taiwan Centers for Disease Control, 6 Linsen S. Road</s1>
<s2>Taipei 10050</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Institute of Biomedical Informatics & Institute of Public Health, National Yang-Ming University, 155 Section 2, Linong Street</s1>
<s2>Taipei 11221</s2>
<s3>TWN</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA20><s1>6463-6468</s1>
</fA20>
<fA21><s1>2014</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20289</s2>
<s5>354000502696130230</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2014 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>35 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>14-0276947</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Vaccine</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background: Pregnant women were prioritized for H1N1 vaccination during the 2009-2010 pandemic. Safety concerns exist with vaccinating pregnant women, particularly in their first trimesters. Methods: We linked computerized data on H1N1 vaccination, National Health Insurance, and Taiwan Birth Registry and identified events of spontaneous abortions (SABs) and all singleton births that occurred/delivered during November 1, 2009-September 30, 2010. The observation period for each case of SAB (6-19 weeks gestation) was divided into period at risk (1-28 days after vaccination) and control periods (the remaining person-days until SAB). The self-controlled case series method for truncated observational periods assessed the incidence rate ratio (IRR) of SAB during the 1-28 days compared with those in the control period. The case-control design matched each case of adverse fetal outcomes to up to 10 controls on fetal sex and year/month of pregnancy onset, and calculated matched odds ratio (OR) on H1N1 vaccination at <14 or ≥ 14 weeks gestation. Results: Sixty-five women with SAB had received H1N1 vaccination at 6-19 weeks gestation. The IRR of SAB for the risk period 1-28 days was 1.03 (95% confidence interval [CI] 0.55-1.93). Among the 147,294 live births and 1354 stillbirths, maternal H1N1 vaccine receipt at <14 weeks gestation was associated with significantly reduced likelihood of small for gestational age (SGA) birth (OR 0.72, 95% CI 0.61-0.84) and birth defect (OR 0.46,95% CI 0.22-1.00), whereas receipt at ≥14 weeks gestation was associated with significantly reduced likelihood of stillbirth (OR 0.63, 95% CI 0.46-0.86), prematurity (OR 0.90, 95% CI 0.83-0.97), low birth weight (OR 0.81, 95% CI 0.74-0.88), and SGA birth (OR 0.90, 95% CI 0.84-0.97). Conclusions: H1N1 vaccination during pregnancy did not increase risk of SAB or adverse fetal outcomes.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05F04</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002A05C10</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Virus grippal A</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Influenza A virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Influenza A virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Vaccination</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Vaccination</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Vacunación</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Gestation</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Pregnancy</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Gestación</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Taiwan</s0>
<s2>NG</s2>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Taiwan</s0>
<s2>NG</s2>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Taiwan</s0>
<s2>NG</s2>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Adjuvant immunologique</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Immunological adjuvant</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Coadyuvante inmunológico</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Vaccin</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Vaccine</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Vacuna</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Virus grippal A(H1N1)</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Influenzavirus A(H1N1)</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Influenzavirus A</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Influenzavirus A</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Influenzavirus A</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Asie</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Asia</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Asia</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Extrême Orient</s0>
<s2>NG</s2>
<s5>13</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Far east</s0>
<s2>NG</s2>
<s5>13</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Extremo Oriente</s0>
<s2>NG</s2>
<s5>13</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Zone subtropicale</s0>
<s5>16</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Subtropical zone</s0>
<s5>16</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Zona subtropical</s0>
<s5>16</s5>
</fC07>
<fN21><s1>349</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 14-0276947 INIST</NO>
<ET>Safety of inactivated monovalent pandemic (H1N1) 2009 vaccination during pregnancy: A population-based study in Taiwan</ET>
<AU>HUANG (Wan-Ting); TANG (Fa-Wei); YANG (Shu-Er); CHIH (Yi-Chien); CHUANG (Jen-Hsiang)</AU>
<AF>Taiwan Centers for Disease Control, 6 Linsen S. Road/Taipei 10050/Taïwan (1 aut., 2 aut., 3 aut., 4 aut., 5 aut.); Institute of Biomedical Informatics & Institute of Public Health, National Yang-Ming University, 155 Section 2, Linong Street/Taipei 11221/Taïwan (5 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Vaccine; ISSN 0264-410X; Coden VACCDE; Royaume-Uni; Da. 2014; Vol. 32; No. 48; Pp. 6463-6468; Bibl. 35 ref.</SO>
<LA>Anglais</LA>
<EA>Background: Pregnant women were prioritized for H1N1 vaccination during the 2009-2010 pandemic. Safety concerns exist with vaccinating pregnant women, particularly in their first trimesters. Methods: We linked computerized data on H1N1 vaccination, National Health Insurance, and Taiwan Birth Registry and identified events of spontaneous abortions (SABs) and all singleton births that occurred/delivered during November 1, 2009-September 30, 2010. The observation period for each case of SAB (6-19 weeks gestation) was divided into period at risk (1-28 days after vaccination) and control periods (the remaining person-days until SAB). The self-controlled case series method for truncated observational periods assessed the incidence rate ratio (IRR) of SAB during the 1-28 days compared with those in the control period. The case-control design matched each case of adverse fetal outcomes to up to 10 controls on fetal sex and year/month of pregnancy onset, and calculated matched odds ratio (OR) on H1N1 vaccination at <14 or ≥ 14 weeks gestation. Results: Sixty-five women with SAB had received H1N1 vaccination at 6-19 weeks gestation. The IRR of SAB for the risk period 1-28 days was 1.03 (95% confidence interval [CI] 0.55-1.93). Among the 147,294 live births and 1354 stillbirths, maternal H1N1 vaccine receipt at <14 weeks gestation was associated with significantly reduced likelihood of small for gestational age (SGA) birth (OR 0.72, 95% CI 0.61-0.84) and birth defect (OR 0.46,95% CI 0.22-1.00), whereas receipt at ≥14 weeks gestation was associated with significantly reduced likelihood of stillbirth (OR 0.63, 95% CI 0.46-0.86), prematurity (OR 0.90, 95% CI 0.83-0.97), low birth weight (OR 0.81, 95% CI 0.74-0.88), and SGA birth (OR 0.90, 95% CI 0.84-0.97). Conclusions: H1N1 vaccination during pregnancy did not increase risk of SAB or adverse fetal outcomes.</EA>
<CC>002A05F04; 002A05C10</CC>
<FD>Virus grippal A; Vaccination; Gestation; Taiwan; Adjuvant immunologique; Vaccin; Virus grippal A(H1N1)</FD>
<FG>Influenzavirus A; Orthomyxoviridae; Virus; Asie; Extrême Orient; Zone subtropicale</FG>
<ED>Influenza A virus; Vaccination; Pregnancy; Taiwan; Immunological adjuvant; Vaccine; Influenzavirus A(H1N1)</ED>
<EG>Influenzavirus A; Orthomyxoviridae; Virus; Asia; Far east; Subtropical zone</EG>
<SD>Influenza A virus; Vacunación; Gestación; Taiwan; Coadyuvante inmunológico; Vacuna</SD>
<LO>INIST-20289.354000502696130230</LO>
<ID>14-0276947</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000021 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000021 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:14-0276947
   |texte=   Safety of inactivated monovalent pandemic (H1N1) 2009 vaccination during pregnancy: A population-based study in Taiwan
}}

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021

	Serveur d'exploration sur les pandémies grippales
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les pandémies grippales

Safety of inactivated monovalent pandemic (H1N1) 2009 vaccination during pregnancy: A population-based study in Taiwan

Safety of inactivated monovalent pandemic (H1N1) 2009 vaccination during pregnancy: A population-based study in Taiwan

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri